Comparison of posaconazole versus weekly amphotericin B lipid complex for the prevention of invasive fungal infections in hematopoietic stem-cell transplantation

Transplantation

Volumn 94, Issue 3, 2012, Pages 302-308

  Chaftari, Anne Marie ^a   Hachem, Ray Y ^a   Ramos, Elizabeth ^a   Kassis, Christelle ^a   Campo, Marcela ^a   Jiang, Ying ^a   Prince, Randall A ^b   Wang, Weiqun ^b   Raad, Issam I ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF HOUSTON   (United States)

Author keywords

Amphotericin B lipid complex; Hematopoietic stem cell transplantation; Invasive fungal infections; Posaconazole

Indexed keywords

ALANINE AMINOTRANSFERASE; AMPHOTERICIN B LIPID COMPLEX; BILIRUBIN; CREATININE; POSACONAZOLE; TACROLIMUS;

ADULT; AGED; APACHE; ARTICLE; CHILL; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIARRHEA; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; ELECTROLYTE DISTURBANCE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HYPOKALEMIA; HYPOMAGNESEMIA; INFECTION PREVENTION; LIVER FUNCTION TEST; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; OPEN STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SYSTEMIC MYCOSIS; VOMITING;

ADMINISTRATION, ORAL; ADULT; AGED; AMPHOTERICIN B; ANTIFUNGAL AGENTS; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFUSIONS, INTRAVENOUS; LEUKEMIA; LIPIDS; LYMPHOMA; MALE; MIDDLE AGED; MYCOSES; PROSPECTIVE STUDIES; RISK; TACROLIMUS; TIME FACTORS; TRANSPLANTATION, HOMOLOGOUS; TRIAZOLES;

EID: 84864692740     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3182577485     Document Type: Article

References (41)

1. Wirk B, Wingard Jr. Current approaches in antifungal prophylaxis in high risk hematologicmalignancy and hematopoietic stemcell transplant patients. Mycopathologia 2009; 168: 299.
2. Wingard JR, Leather H. A new era of antifungal therapy. Biol Blood Marrow Transplant 2004; 10: 73.
3. Fukuda T, Boeckh M, Carter RA, et al. Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning. Blood 2003; 102: 827.
4. Prentice HG, Kibbler CC, Prentice AG. Towards a targeted, risk-based, antifungal strategy in neutropenic patients. Br JHaematol 2000; 110: 273.
5. Marr KA. Antifungal prophylaxis in hematopoietic stem cell transplant recipients. Curr Opin Infect Dis 2001; 14: 423.
6. Martino R, Cortes M, Subira M, et al. Efficacy and toxicity of intermediate-dose amphotericin B lipid complex as a primary or salvage treatment of fungal infections in patients with hematological malignancies. Leuk Lymphoma 2005; 46: 1429.
7. Ito JI, Chandrasekar PH, Hooshmand-Rad R. Effectiveness of amphotericin B lipid complex (ABLC) treatment in allogeneic hematopoietic cell transplant (HCT) recipients with invasive aspergillosis (IA). Bone Marrow Transplant 2005; 36: 873.
8. Ito JI, Hooshmand-Rad R. Treatment of Candida infections with amphotericin B lipid complex. Clin Infect Dis 2005; 40(suppl 6): S384.
9. Chandrasekar PH, Ito JI. Amphotericin B lipid complex in the management of invasive aspergillosis in immunocompromised patients. Clin Infect Dis 2005; 40(suppl 6): S392.
10. Raad II, Hachem RY, Herbrecht R, et al. Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions. Clin Infect Dis 2006; 42: 1398.
11. Ullmann AJ, Cornely OA, Burchardt A, et al. Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection. Antimicrob Agents Chemother 2006; 50: 658.
12. Torres HA, Hachem RY, Chemaly RF, et al. Posaconazole: a broadspectrum triazole antifungal. Lancet Infect Dis 2005; 5: 775.
13. Hachem RY, Kontoyiannis DP, Boktour MR, et al. Aspergillus terreus: an emerging amphotericin BYresistant opportunistic mold in patients with hematologic malignancies. Cancer 2004; 101: 1594.
14. Raad II, Graybill JR, Bustamante AB, et al. Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections. Clin Infect Dis 2006; 42: 1726.
15. Strasfeld L, Weinstock DM. Antifungal prophylaxis among allogeneic hematopoietic stem cell transplant recipients: current issues and new agents. Expert Rev Anti Infect Ther 2006; 4: 457.
16. Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia.NEngl J Med 2007; 356: 348.
17. Ullmann AJ, Lipton JH, Vesole DH, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007; 356: 335.
18. Maertens J, Marchetti O, Herbrecht R, et al. European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3-2009 update. Bone Marrow Transplant. 2011; 46: 709.
19. Marr KA, Bow E, Chiller T, et al. Fungal infection prevention after hematopoietic cell transplantation. BoneMarrow Transplant 2009; 44: 483.
20. Jansen J, Akard LP, Wack MF, et al. Delayed ABLC prophylaxis after allogeneic stem-cell transplantation. Mycoses 2006; 49: 397.
21. Wingard JR, White MH, Anaissie E, et al. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group. Clin Infect Dis 2000; 31: 1155.
22. Mattiuzzi GN, Kantarjian H, Faderl S, et al. Amphotericin B lipid complex as prophylaxis of invasive fungal infections in patients with acute myelogenous leukemia and myelodysplastic syndrome undergoing induction chemotherapy. Cancer 2004; 100: 581.
23. Gubbins PO, Amsden JR, McConnell SA, et al. Pharmacokinetics and buccal mucosal concentrations of a 15 milligram per kilogram of body weight total dose of liposomal amphotericin B administered as a single dose (15 mg/kg), weekly dose (7.5 mg/kg), or daily dose (1 mg/kg) in peripheral stem cell transplant patients. Antimicrob Agents Chemother 2009; 53: 3664.
24. El-Cheikh J, Faucher C, Furst S, et al. High-dose weekly liposomal amphotericin B antifungal prophylaxis following reduced-intensity conditioning allogeneic stem cell transplantation. Bone Marrow Transplant 2007; 39: 301.
25. Mehta P, Vinks A, Filipovich A, et al. High-dose weekly AmBisome antifungal prophylaxis in pediatric patients undergoing hematopoietic stem cell transplantation: a pharmacokinetic study. Biol Blood Marrow Transplant 2006; 12: 235.
26. U.S. Department of Health and Human Services, NIH, NCI. Cancer Therapy Evaluation Program, Common terminology criteria for adverse events (CTCAE) Version 3.0, 2003. (http://ctep.cancer.gov). Publish Date: August 9, 2006.
27. Pagano L, Caira M, Nosari A, et al. Fungal infections in recipients of hematopoietic stem cell transplants: results of the SEIFEM B-2004 studyVSorveglianza Epidemiologica Infezioni Fungine Nelle Emopatie Maligne. Clin Infect Dis 2007; 45: 1161.
28. Jantunen E, Ruutu P, Niskanen L, et al. Incidence and risk factors for invasive fungal infections in allogeneic BMT recipients. Bone Marrow Transplant 1997; 19: 801.
29. Sabatelli F, Patel R, Mann PA, et al. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. Antimicrob Agents Chemother 2006; 50: 2009.
30. Espinel-Ingroff A. Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J Clin Microbiol 1998; 36: 2950.
31. Pfaller MA, Messer SA, Hollis RJ, et al. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000. Antimicrob Agents Chemother 2002; 46: 1032.
32. van Burik JA, Hare RS, Solomon HF, et al. Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. Clin Infect Dis 2006; 42: e61.
33. Walsh TJ, Raad I, Patterson TF, et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis 2007; 44: 2.
34. Krishna G, Moton A, Ma L, et al. Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. Antimicrob Agents Chemother 2009; 53: 958.
35. Krishna G, Ma L, Vickery D, et al. Effect of varying amounts of a liquid nutritional supplement on the pharmacokinetics of posaconazole in healthy volunteers. Antimicrob Agents Chemother 2009; 53: 4749.
36. Andes D, Pascual A, Marchetti O. Antifungal therapeutic drug monitoring: established and emerging indications. Antimicrob Agents Chemother 2009; 53: 24.
37. El Cheikh J, Castagna L, Wang L, et al. Once-weekly liposomal amphotericin B for prophylaxis of invasive fungal infection after graftversus-host disease in allogeneic hematopoietic stem cell transplantation: a comparative retrospective single-center study. Hematol Oncol Stem Cell Ther 2010; 3: 167.
38. Cordonnier C, Mohty M, Faucher C, et al. Safety of a weekly high dose of liposomal amphotericin B for prophylaxis of invasive fungal infection in immunocompromised patients: PROPHYSOME Study. Int J Antimicrob Agents 2008; 31: 135.
39. Dodds-Ashley E. Management of drug and food interactions with azole antifungal agents in transplant recipients. Pharmacotherapy 2010; 30: 842.
40. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31.
41. De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008; 46: 1813.